mRNA新冠疫苗安全性与机制问题的循证评估
本文针对mRNA新冠疫苗的恶性肿瘤、自身免疫病、全因死亡增加等安全性疑问及DNA污染、抗原持续等机制假设,整合非临床、临床、药物流行病学与监管证据进行定性评估。证据不支持疫苗导致长期死亡、恶性肿瘤、自身免疫病或基因毒性风险增加,残留DNA在监管限值内且无基因组整合机制,真实世界研究显示接种者全因死亡更低。
要点
- 现有证据不支持mRNA新冠疫苗增加长期死亡、恶性肿瘤或自身免疫病风险。
- 残留DNA水平在验证方法下符合监管限值,无可信机制支持基因组整合。
- 真实世界研究显示接种者全因死亡率低于未接种者。
核心结论
- 综合非临床、临床、药物流行病学和监管证据,不支持mRNA新冠疫苗导致长期死亡、恶性肿瘤、自身免疫病或基因毒性等安全性问题。
- 多项大型人群研究显示接种者全因死亡率低于未接种者。
- 残留DNA在验证方法下符合监管限值,无基因组整合机制;生物分布限于注射部位和淋巴组织,无持续存在。
研究设计与样本
- 靶向叙述性综述,定性评估已发表文献、监管评估和监测数据,考量生物学合理性、方法学严谨性和独立数据源一致性。
主要发现
- 证据不支持mRNA新冠疫苗接种增加长期死亡率、恶性肿瘤、自身免疫病或基因毒性风险。
- 大型人群研究报道接种者全因死亡率更低。
- IgG4亚类应答未在真实世界疫苗有效性研究中与保护力受损相关。
临床怎么用
- 疫苗安全性问题应使用透明、结构化框架评估,系统权衡获益、危害、证据质量、价值和可行性。
- 持续监测和严格评估对公共卫生政策制定仍至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Messenger RNA (mRNA) COVID-19 vaccines have been administered globally at unprecedented scale and have demonstrated strong effectiveness against severe disease, hospitalization, and death. Extensive safety monitoring across randomized clinical trials, national surveillance systems, and global pharmacovigilance programs has consistently supported a favorable benefit-risk profile for these vaccines. Despite this evidence, a range of questions and mechanistic hypotheses continue to circulate, including assertions of increased risk of malignancies, autoimmune diseases, and all-cause mortality, as well as proposed mechanisms involving product-related impurities (e.g. DNA contamination), biodistribution and antigen persistence, non-canonical translation (e.g. ribosomal frame-shifting), and immune modulation. This targeted narrative review synthesizes nonclinical, clinical, pharmacoepidemiologic, and regulatory evidence relevant to these mechanistic and safety related questions. Published literature, regulatory assessments, and surveillance data were qualitatively evaluated in the context of biological plausibility, methodological rigor, and consistency across independent data sources. Across the body of evidence, findings do not support increased long-term mortality, malignancy, autoimmune disease, genotoxicity or other long-term safety issues attributable to mRNA COVID-19 vaccination. On the contrary, several large population-based studies have reported lower all-cause mortality among vaccinated individuals. Residual DNA levels are within established regulatory limits when measured using validated methods, and no credible mechanism supports genomic integration. Biodistribution studies demonstrate expected localization to the injection site and lymphoid tissues with no persistence. Immunologic findings, including IgG4 subclass responses, have not been associated with impaired protection in real-world vaccine effectiveness studies. Collectively, the evidence supports the safety and effectiveness of mRNA COVID-19 vaccines. Ongoing surveillance and rigorous evaluation remain essential to inform public health policy. Importantly, vaccine safety questions should be assessed using transparent, structured frameworks that systematically weigh benefits, harms, quality of evidence, values, and feasibility.
引用
- Sohn WY, Goody SMG, Reid DW, et al. Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines. Vaccine. 2026. PMID: 41740458. doi:10.1016/j.vaccine.2026.128394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。